We are live on ! Find out more
CASC

Cascadian Therapeutics, Inc.
CASC

Delisted

CASC was delisted on the 8th of March, 2018.

Back to rankings

63 hedge funds and large institutions have $62.8M invested in Cascadian Therapeutics, Inc. in 2013 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 14 increasing their positions, 22 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

362% more call options, than puts

Call options by funds: $4.04M | Put options by funds: $874K

42% more capital invested

Capital invested by funds: $44.3M → $62.8M (+$18.4M)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

5% less funds holding

Funds holding: 66 → 63 (-3)

14% less first-time investments, than exits

New positions opened: 12 | Existing positions closed: 14

36% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 22

Holders
63
Holders Change
-3
Holders Change %
-4.55%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
12
Increased
14
Reduced
22
Closed
14
Calls
$4.04M
Puts
$874K
Net Calls
+$3.17M
Net Calls Change
+$275K

Top Buyers

Rank Fund Capital Flow
1
QF
QVT Financial
New York
+$6.78M
2
First Eagle Investment Management
First Eagle Investment Management
New York
+$1.72M
3
BI
BVF Inc
California
+$1.37M
4
SM
Sabby Management
Florida
+$1.16M
5
PC
PointState Capital
New York
+$877K

Top Sellers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
-$3.56M
2
Millennium Management
Millennium Management
New York
-$3M
3
Northern Trust
Northern Trust
Illinois
-$823K
4
Morgan Stanley
Morgan Stanley
New York
-$448K
5
Deutsche Bank
Deutsche Bank
Germany
-$430K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$288K -$291K -27,692 -54%
Morgan Stanley
27
Morgan Stanley
New York
$224K -$448K -42,541 -70%
Northern Trust
28
Northern Trust
Illinois
$181K -$823K -78,206 -84%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$166K – – –
TC
30
TFS Capital
Pennsylvania
$151K -$334K -31,700 -72%
ARTA
31
A.R.T. Advisors
New York
$130K +$84.6K +8,034 +316%
WMSA
32
Weiss Multi-Strategy Advisers
New York
$121K +$103K +9,829 New
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$98K -$3.85K -366 -4%
Citigroup
34
Citigroup
New York
$97K +$21.6K +2,050 +35%
Nomura Holdings
35
Nomura Holdings
Japan
$76K -$56.1K -5,328 -46%
VKH
36
Virtu KCG Holdings
New York
$75K +$64K +6,078 New
DekaBank Deutsche Girozentrale
37
DekaBank Deutsche Girozentrale
Germany
$73K +$61.8K +5,867 New
HK
38
Horizon Kinetics
New York
$67K – – –
State Street
39
State Street
Massachusetts
$61K -$874 -83 -2%
Dimensional Fund Advisors
40
Dimensional Fund Advisors
Texas
$58K -$1.29K -123 -3%
LTFS
41
Ladenburg Thalmann Financial Services
Florida
$55K – – –
Charles Schwab
42
Charles Schwab
California
$53K – – –
JP Morgan Chase
43
JP Morgan Chase
New York
$51K -$3.56M -337,861 -99%
ProShare Advisors
44
ProShare Advisors
Maryland
$46K -$45.3K -4,301 -54%
GF
45
Gerstein Fisher
New York
$31K +$26.3K +2,500 New
Wells Fargo
46
Wells Fargo
California
$24K +$13.3K +1,266 +199%
U
47
UBS
Switzerland
$22K -$24.7K -2,343 -57%
BA
48
BlackRock Advisors
Delaware
$22K – – –
PCM
49
Prelude Capital Management
New York
$19K +$15.9K +1,515 New
Creative Planning
50
Creative Planning
Kansas
$17K -$589 -56 -4%
1
2
3

CASC Hedge Fund Activity: Q3 2013 in Review

63 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Cascadian Therapeutics, Inc. (CASC) for Q3 2013, worth a combined $62.8M — up 42% from $44.3M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of CASC and 12 opened new positions — a net loss of 2 holders — while 22 trimmed existing stakes and 14 added.

The largest buyer was QVT Financial, opening a new position worth an estimated $6.78M. The largest seller was JP Morgan Chase, cutting an estimated $3.56M.

  • 63 institutional investors held Cascadian Therapeutics, Inc. (CASC) as of Q3 2013, down from 66 in Q2 2013.
  • Funds reported $62.8M of Cascadian Therapeutics, Inc. stock for Q3 2013, up 42% quarter-over-quarter.
  • 12 funds opened new Cascadian Therapeutics, Inc. positions in Q3 2013 and 14 closed out, a net change of -2 holders.
  • The largest Cascadian Therapeutics, Inc. buyer in Q3 2013 was QVT Financial, an estimated $6.78M added.
  • The largest Cascadian Therapeutics, Inc. seller in Q3 2013 was JP Morgan Chase, an estimated $3.56M sold.

Based on aggregated 13F filings for Q3 2013.